Arava Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Arava Indications
Indications
Arava Dosage and Administration
Adult
Children
Renal Impairment
Use caution when administering Arava to patients with renal impairment as the kidneys play a role in drug elimination.
Hepatic Impairment
Arava is not recommended for patients with hepatic impairment given the need to metabolize leflunomide into the active species, the role of the liver in drug elimination/recycling and the possible increased risk of hepatotoxicity.
Other Modifications
Females of reproductive age who wish to get pregnant should discontinue Arava and undergo an accelerated drug elimination procedure to achieve a plasma teriflunomide concentration of <0.02mg/L.
Use effective contraception during treatment with Arava and while undergoing a drug elimination procedure until verification that plasma teriflunomide is <0.02mg/L.
Arava Contraindications
Contraindications
Arava Boxed Warnings
Boxed Warning
Arava Warnings/Precautions
Warnings/Precautions
Arava Pharmacokinetics
Absorption
Peak teriflunomide concentrations: 6-12 hours after dosing.
Teriflunomide has a very long half-life (18-19 days); a loading dose of 100mg for 3 days was used to facilitate steady-state teriflunomide concentrations in clinical trials. Without a loading dose, it is estimated that attainment of steady state plasma concentrations would require about 2 months of dosing.
Distribution
Teriflunomide is extensively bound to plasma protein (>99%).
Elimination
Teriflunomide has a median half-life of 18-19 days. Without an accelerated drug elimination procedure, it may take up to 2 years to reach plasma teriflunomide concentrations of <0.02mg/L.
Teriflunomide is eliminated by direct biliary excretion as well as renal excretion.
Arava Interactions
Interactions
Arava Adverse Reactions
Adverse Reactions
Arava Clinical Trials
Arava Note
Not Applicable